News & Videos - BRISTOL-MYERS SQUIBB CO.

NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company: At Bristol Myers Squibb, our vision is to transform patients' lives through science Originally published on Bristol Myers Squibb News & Perspectives Since 1887, BMS has enabled positive change for patients around the world, and I am honored to continue this legacy as Board Chair and CEO. Our obligation to advance this legacy is profound. It calls for us to honor and uphold the values and principles that are the...

Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity NORTHAMPTON, MA / ACCESSWIRE / April 8, 2024 / Bristol Myers Squibb Company Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company's ESG strategy is embedded in its mission to discover, develop, and deliver...

Company builds on its strengths to advance patient access, product innovation, culture and inclusion and diversity PRINCETON, NJ / ACCESSWIRE / April 2, 2024 / Bristol Myers Squibb Company Originally published on Bristol Myers Squibb News & Perspectives Bristol Myers Squibb (NYSE:BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company's meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts. The company's ESG strategy...

Company Awards $1.8M in Grants to Eight Organizations in Brazil, India, Thailand and the United Kingdom Originally published on Bristol Myers Squibb Newsroom PRINCETON, NJ / ACCESSWIRE / March 29, 2024 / Bristol Myers Squibb (NYSE: BMY) unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health (SDoH) in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom. The new health equity grants are an...

Bristol Myers Squibb Company ranks in top 10 of Pharmaceutical and Biotech Sector on the issues Americans care about most PRINCETON, NJ / ACCESSWIRE / February 5, 2024 / Bristol Myers Squibb (NYSE:BMY) is honored to announce it has been recognized as One of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, recognized BMS for its commitment to key social responsibilities, including employees, customers, communities, and environmental impact. Bristol Myers Squibb...

Danielle Menture, BMS' vice president of sustainability, answers five questions about what the company is doing to meet its green energy goals. NORTHAMPTON, MA / ACCESSWIRE / November 17, 2023 / Bristol Myers Squibb Company Photo Credit: National Grid Renewables Originally published on Bristol Myers Squibb News & Perspectives This week, BMS announced a 15-year virtual power purchase agreement (VPPA) with National Grid Renewables for 145 megawatts (MW) of solar at the Texas-based Blevins Project....

NORTHAMPTON, MA / ACCESSWIRE / January 5, 2023 / Bristol Myers Squibb Company: Originally published on Bristol Myers Squibb News & Perspectives "A bicycle ride around the world begins with a single pedal stroke." A handful of inspirational words from author Scott Stoll served as the rallying cry for more than 350 Bristol Myers Squibb employees representing 23 nations who successfully trained and participated in four regional bicycle rides collectively known as C2C4C. The 2022 C2C4C journey...

NORTHAMPTON, MA / ACCESSWIRE / December 20, 2022 / Bristol Myers Squibb Company Bristol Myers Squibb has a long-standing partnership with the Leukemia and Lymphoma Society (LLS) and has been the top biopharma fundraising team for Light The Night® for more than a decade. Since 1949, the LLS has invested nearly $1.5 billion in cancer research. While Light The Night is a U.S.-based event, it supports the LLS, a global leader in cancer research. In late October, as Asalia Goldberg and her fellow...

NORTHAMPTON, MA / ACCESSWIRE / December 6, 2022 / Bristol Myers Squibb Company: For too many years, cancer patients in Lesotho felt life-changing cancer treatment was out of reach. No oncology clinics existed in their landlocked country ringed by steep mountains and surrounded by South Africa. Those hoping to receive treatment journeyed hours, traversing mountains to reach Bloemfontein, South Africa. Some patients crossed the ocean to India, staying for many weeks of treatment away from their...

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. “We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb. The MyoKardia team has revolutionized cardiovascular treatments...

Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of MyoKardia for a purchase price of $225.00 per share in cash, or approximately $13.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on November 3, 2020. This press...

Thinking about buying stock in Apple, Bristol-Myers Squibb, Cronos Group, Coca-Cola, or Walgreens Boots Alliance? PR Newswire NEW YORK, Nov. 12, 2019 NEW YORK , Nov. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, BMY, CRON, KO, and WBA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AAPL:...

Bristol hospital introduces 'zero tolerance' policy on staff abuse RT UK is a channel based in London covering British news and politics, protests and interviews ......

Bristol-Myers Squibb Company (NYSE: BMY) today announced that CheckMate -9LA, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC), met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis. The comparator in this study was chemotherapy alone for up to four cycles followed by optional maintenance...

The University of Bristol Selects Signant Health's TrialConsent® to Assess the Impact and Value of eConsent in an Oncology Trial PR Newswire PHILADELPHIA, Oct. 14, 2019 The Prestigious UK Academic Institution selected TrialConsent® to Administer eConsent to Benefit Sites and Patients in Future Clinical Research PHILADELPHIA , Oct. 14, 2019 /PRNewswire/ -- The National Institute for Health Research Bristol Biomedical Research Centre (NIHR Bristol BRC) at the University of Bristol has selected...

Thinking about buying stock in Bristol-Myers Squibb, Canopy Growth Corp, Intel, Target, or Tilray? PR Newswire NEW YORK, Oct. 10, 2019 NEW YORK , Oct. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BMY, CGC, INTC, TGT, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. BMY:...

Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. today announced results from the Phase 3 ATTRACTION-3 trial evaluating Opdivo (nivolumab) versus chemotherapy (docetaxel or paclitaxel) for the treatment of patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs. For the primary endpoint of overall survival (OS), Opdivo demonstrated a...

Bristol-Myers Squibb Company (NYSE: BMY) today announced results from Part 1 of the Phase 3 CheckMate -227 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC). Opdivo plus low-dose Yervoy met the independent co-primary endpoint of overall survival, demonstrating superior benefit compared to chemotherapy in patients whose tumors expressed PD-L1 ≥1% [Hazard Ratio (HR) 0.79; 97.72% Confidence...

Bristol-Myers Squibb Company (NYSE: BMY) today announced results of a three-year analysis of efficacy data from the Phase 3 CheckMate -238 study evaluating adjuvant use of Opdivo (nivolumab) 3 mg/kg versus Yervoy (ipilimumab) 10 mg/kg in patients with Stage III or Stage IV melanoma who were at high risk of recurrence following complete surgical resection. At three years of follow-up, Opdivo continues to demonstrate superior recurrence-free survival (RFS) compared to Yervoy , the active control,...

Bristol-Myers Squibb Company (NYSE: BMY) today announced five-year results from the Phase 3 CheckMate -067 clinical trial, which continues to demonstrate improved overall survival with the first-line combination of Opdivo (nivolumab) plus Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced metastatic melanoma. With a minimum follow-up of 60 months (five years), five-year overall survival rates were 52% for the Opdivo plus Yervoy combination, 44% for Opdivo alone, and 26% for...